OKYO Pharma Limited - Ordinary Shares (OKYO)

Competitors to OKYO Pharma Limited - Ordinary Shares (OKYO)

Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals is focused on developing ophthalmic therapies for glaucoma and other diseases, which overlaps with some of OKYO's targeted areas. Aerie's competitive advantage is their established products and ongoing clinical trials that enhance their market presence, while OKYO is still developing its product portfolio.

EyePoint Pharmaceuticals, Inc. 

EyePoint Pharmaceuticals specializes in innovative therapies for serious eye diseases. Similar to OKYO, they focus on developing sustained release drug delivery systems. Their established product pipeline and experience in ocular therapeutics give them a competitive edge over OKYO, making them a prominent threat in the market for treating eye-related conditions.

Harrow Health, Inc. 

Harrow Health focuses on the ophthalmic pharmaceuticals sector and is known for its commercialization of medications for eye diseases. They possess a strong market presence and a comprehensive suite of products that can create hurdles for emerging firms like OKYO. Their competitive advantage lies in their established relationships with healthcare providers and distribution channels.

Ocular Therapeutix, Inc. 

Ocular Therapeutix is engaged in developing and commercializing innovative therapies for treating diseases and conditions of the eye, similar to OKYO. Their competitive advantage is derived from their proprietary drug delivery technology, which allows for extended treatment durations, thus enhancing patient compliance. Ocular's established clinical results may pose significant competition for OKYO.

Zymeworks Inc.

Although Zymeworks focuses primarily on larger therapeutic areas such as oncology, they have been expanding into ophthalmic applications, which puts them in competition with OKYO. Their extensive resources, including a well-funded pipeline and a robust platform technology, provide them with a distinct advantage in research and development capabilities.